William Burke Sells 2,207 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 2,207 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total transaction of $43,786.88. Following the completion of the sale, the director owned 23,022 shares of the company’s stock, valued at approximately $456,756.48. The trade was a 8.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CeriBell Price Performance

CBLL opened at $19.55 on Friday. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33. The firm has a market capitalization of $741.73 million, a P/E ratio of -11.99 and a beta of 0.77. The company’s 50-day moving average is $18.78 and its 200 day moving average is $19.72. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. Research analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of CeriBell during the 1st quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell in the third quarter valued at approximately $33,000. CWM LLC lifted its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the period.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Canaccord Genuity Group reduced their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.